A Long-Term Safety and Efficacy Study of Eszopiclone in Elderly With Primary Chronic Insomnia
Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
To evaluate the long-term safety and efficacy of eszopiclone administered for 12 weeks in
elderly subjects with primary chronic insomnia.Administration of eszopiclone 2 mg daily at
bedtime for 12 weeks in elderly subjects with a diagnosis of primary chronic insomnia will be
safe and well tolerated, improve subjective sleep measures, improve measures of Quality of
Life and next day insomnia symptoms, and have no significant withdrawal central nervous
system adverse events or rebound insomnia.